The American Cancer Society (ACS) describes hyperthermia’s benefits with hedged language — “local hyperthermia may destroy tumors without surgery” and “regional and whole-body hyperthermia seem to help other treatments work better” — rather than guaranteeing claims.
What exactly does ACS say?
ACS’s public materials state:
- “Local hyperthermia, such as RFA, can destroy tumors without surgery.”
- “Regional and whole-body hyperthermia seem to make other forms of cancer treatment work better. Heating the temperature of cancer cells above normal makes them easier to be killed by radiation therapy and certain chemo drugs.”
The benefit descriptions above are drawn from ACS public educational materials and reflect a general research direction within a U.S. medical context. Actual effects vary by individual condition, cancer type, and treatment plan. This does not mean any specific medical device has been proven to have this effect, nor is it a Taiwan-approved efficacy claim. Effectiveness still depends on individual circumstances and physician assessment.
Are these benefits already established?
No. NCI explicitly states that whether hyperthermia helps patients live longer “is also not clear” — meaning current benefit descriptions remain at the level of a research direction, without a settled or consistent conclusion. See Current Research Status for details.
Have hyperthermia's benefits already been proven?
Current public educational materials use hedged terms like "seem to" and "may" to describe benefits, not a definitive proven conclusion, and explicitly state that whether it helps people live longer is not clear. Actual effects vary by individual, so decisions should be made with a physician's assessment rather than assuming a specific outcome.
Last updated: 2026-08-16 | Sources: American Cancer Society (ACS), “Hyperthermia to Treat Cancer” (updated 2025-04-07); National Cancer Institute (NCI), “Hyperthermia to Treat Cancer” (updated 2025-05-15). If content differs from the latest research, the latest publicly available information takes precedence — please also consult your care team.